Resmed tanks overnight on trial failure
![](https://assets.livewiremarkets.com/rails/active_storage/representations/proxy/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBYTg9IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--39e69bd3b68ed62cda736d78909192fa6b58850d/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCem9MWm05eWJXRjBTU0lJY0c1bkJqb0dSVlE2RTNKbGMybDZaVjkwYjE5bWFXeHNXd2RwQWNocEFjZz0iLCJleHAiOm51bGwsInB1ciI6InZhcmlhdGlvbiJ9fQ==--c306068f01ab83c3650795f1865f4e6da1f93433/LWM-icon-exclusive.png)
Livewire
The SMH reports that "Medical device maker ResMed has said a major clinical trial that sought to show its sleep therapy products protected heart attack victims, actually put their lives at further risk. The shock clinical trial result will be a major disappointment for ResMed investors who were counting on a positive result to open the door for the company to play a role in the treatment of heart failure, which costs the US government alone $US35 billion each year. (VIEW LINK)
2 topics
1 stock mentioned
![Livewire Equities](https://assets.livewiremarkets.com/rails/active_storage/representations/proxy/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBYTg9IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--39e69bd3b68ed62cda736d78909192fa6b58850d/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCem9MWm05eWJXRjBTU0lJY0c1bkJqb0dSVlE2RTNKbGMybDZaVjkwYjE5bWFXeHNXd2RwQWNocEFjZz0iLCJleHAiOm51bGwsInB1ciI6InZhcmlhdGlvbiJ9fQ==--c306068f01ab83c3650795f1865f4e6da1f93433/LWM-icon-exclusive.png)
The Livewire Equities feed brings you a range of insights that relate to Australian equities
Expertise
No areas of expertise
![Livewire Equities](https://assets.livewiremarkets.com/rails/active_storage/representations/proxy/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBYTg9IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--39e69bd3b68ed62cda736d78909192fa6b58850d/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCem9MWm05eWJXRjBTU0lJY0c1bkJqb0dSVlE2RTNKbGMybDZaVjkwYjE5bWFXeHNXd2RwQWNocEFjZz0iLCJleHAiOm51bGwsInB1ciI6InZhcmlhdGlvbiJ9fQ==--c306068f01ab83c3650795f1865f4e6da1f93433/LWM-icon-exclusive.png)
The Livewire Equities feed brings you a range of insights that relate to Australian equities
Expertise
No areas of expertise